Combivir

RSS

lamivudine / zidovudine

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report (EPAR) for Combivir. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Combivir.

For practical information about using Combivir, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 22/02/2018

Authorisation details

Product details
Name
Combivir
Agency product number
EMEA/H/C/000190
Active substance
  • lamivudine
  • zidovudine
International non-proprietary name (INN) or common name
lamivudine / zidovudine
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AR01
Publication details
Marketing-authorisation holder
ViiV Healthcare UK Limited 
Revision
27
Date of issue of marketing authorisation valid throughout the European Union
17/03/1998
Contact address
ViiV Healthcare UK Limited
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom

Product information

24/01/2018 Combivir - EMEA/H/C/000190 - WS/1156

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Combivir is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV) infection.

Assessment history

How useful was this page?

Add your rating